A spokesperson for Novartis has confirmed to OINDPnews that Mylan exercised an option to acquire a San Carlos, CA, USA manufacturing facility for TOBI inhaled tobramycin products in May 2019 and is expected to acquire the site assets in September 2019. Mylan paid approximately $463 million to Novartis for worldwide rights to TOBI Podhaler DPI and TOBI inhalation solution in September 2018.
Novartis acquired the facility in 2008 when it acquired Nektar’s pulmonary business. At that time, the plant had approximately 140 employees. According to the Novartis spokesperson, almost all of the employees currently working at the San Carlos facility are expected to join Mylan. Presumably the personnel would become employees of the new company that will be formed by Mylan’s recently announced merger with Upjohn.
